Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2012

Open Access 01-12-2012 | Primary research

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Authors: Thomas R Einarson, Maria Geitona, Alexandros Chaidemenos, Vasiliki Karpouza, Theodoros Mougiakos, Periklis Paterakis, Dimitrios Ploumpidis, Dionyssios Potamitis-Komis, Roman Zilbershtein, Colin Vicente, Charles Piwko, Panagiotis Kakkavas, Konstantina Paparouni, Rasmus C D Jensen, Michiel E H Hemels

Published in: Annals of General Psychiatry | Issue 1/2012

Login to get access

Abstract

Background

Patients having chronic schizophrenia with frequent relapses and hospitalizations represent a great challenge, both clinically and financially. Risperidone long-acting injection (RIS-LAI) has been the main LAI atypical antipsychotic treatment in Greece. Paliperidone palmitate (PP-LAI) has recently been approved. It is dosed monthly, as opposed to biweekly for RIS-LAI, but such advantages have not yet been analysed in terms of economic evaluation.

Purpose

To compare costs and outcomes of PP-LAI versus RIS-LAI in Greece.

Methods

A cost-utility analysis was performed using a previously validated decision tree to model clinical pathways and costs over 1 year for stable patients started on either medication. Rates were taken from the literature. A local expert panel provided feedback on treatment patterns. All direct costs incurred by the national healthcare system were obtained from the literature and standard price lists; all were inflated to 2011 costs. Patient outcomes analyzed included average days with stable disease, numbers of hospitalizations, emergency room visits, and quality-adjusted life-years (QALYs).

Results

The total annual healthcare cost with PP-LAI was €3529; patients experienced 325 days in remission and 0.840 QALY; 28% were hospitalized and 15% received emergency room treatment. With RIS-LAI, the cost was €3695, patients experienced 318.6 days in remission and 0.815 QALY; 33% were hospitalized and 17% received emergency room treatment. Thus, PP-LAI dominated RIS-LAI. Results were generally robust in sensitivity analyses with PP-LAI dominating in 74.6% of simulations. Results were sensitive to the price of PP-LAI.

Conclusions

PP-LAI appears to be a cost-effective option for treating chronic schizophrenia in Greece compared with RIS-LAI since it results in savings to the health care system along with better patient outcomes.
Appendix
Available only for authorised users
Literature
1.
Glazer W, Ereshefsky L: A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry. 1996, 57: 337-345.PubMed
2.
Karagianis J, Novick D, Pecenak J, Haro JM, Dossenbach M, Treuer T, Montgomery W, Walton R, Lowry AJ: Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract. 2009, 63: 1578-1588. 10.1111/j.1742-1241.2009.02191.x.CrossRefPubMed
3.
Nasrallah H: The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007, 115: 260-267. 10.1111/j.1600-0447.2006.00982.x.CrossRefPubMed
4.
Weiden P, Zygmunt A: Medication noncompliance in schizophrenia. Part I. Assessment. J Pract Psychiatry Behav Health. 1997, 3: 106-110.
5.
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S: Oral versus depot antipsychotic drugs for schizophrenia: A critical systematic review and meta-analysis of randomised long-term trials. Schiz Res. 2011, 127: 83-92. 10.1016/j.schres.2010.11.020.CrossRef
6.
Möller HJ: Novel antipsychotics and negative symptoms. Int Clin Psychopharmacol. 1998, 13 (Suppl 3): S43-S47.CrossRefPubMed
7.
Kane J, Eerdekens M, Lindenmayer J-P, Keith S, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003, 160: 1125-1132. 10.1176/appi.ajp.160.6.1125.CrossRefPubMed
8.
Möller HJ: Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs. 2007, 67: 1541-1566. 10.2165/00003495-200767110-00003.CrossRefPubMed
9.
Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, Limosin F, Beaufils B, Vaiva G, Verdoux H, Moride Y, Fabre A, Thibaut F, Abenhaim L, for the CGS Study Group: Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schiz Res. 2012, 134: 187-194. 10.1016/j.schres.2011.10.022.CrossRef
10.
11.
12.
13.
Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M: Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schiz Res. 2010, 116: 107-117. 10.1016/j.schres.2009.10.026.CrossRef
14.
Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D: A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2010, 25: 685-697.CrossRefPubMed
15.
Fleischhacker WW, Gopal S, Lane L, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Marielle Eerdekens M: A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2011, Jul 22: 1-12. 10.1017/S1461145711001076..
16.
Hough D, Lindenmayer J-P, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M: Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33: 1022-1031. 10.1016/j.pnpbp.2009.05.014.CrossRefPubMed
17.
Coppola D, Liu Y, Gopal S, Remmerie B, Samtani M, Pandina G, Hough D, Nuamah I, Sulaiman A: Long-term safety, tolerability and pharmacokinetics of paliperidone palmitate: a one-year open-label study in patients with schizophrenia. 2010, Presented at the 163rd Annual Meeting of the American Psychiatric Association, New Orleans, LA
18.
Furiak N, Ascher-Svanum H, Klein R, Smolen LJ, Lawson AH, Montgomery W, Conley RR: Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin. 2011, 27: 713-740. 10.1185/03007995.2011.554533.CrossRefPubMed
19.
Haycox A: Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. PharmacoEconomics. 2005, 23 (Suppl 1): 3-16.CrossRefPubMed
20.
Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study. Ann General Psychiatry. 2008, 7: 16-10.1186/1744-859X-7-16.CrossRef
21.
Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L: Schizophrenia: medical illness, mortality, and aging. Int J Psychiatry Med. 2011, 43: 245-251.CrossRef
22.
Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bø CN, Pudas H, Hemels MEH: Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. Acta Neuropsychiatr 2012 (in press). 2012, 10.1111/j.1601-5215.2012.00670.x. (in press)
23.
Simonsen E, Friis S, Opjordsmoen S, Mortensen EL, Haahr U, Melle I, Joa I, JO Johan nessen, Larsen TK, Røssberg JI, Rund BR, Vaglum P, McGlashan TH: Early identification of non-remission in first-episode psychosis in a two-year outcome study. Acta Psychiatr Scand. 2010, 122: 375-383. 10.1111/j.1600-0447.2010.01598.x.CrossRefPubMed
24.
Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry. 1999, 156: 990-999.PubMed
25.
Geitona M, Xaplanteris L: Data collection and conduction of pharmacoeconomic studies in Greece. Eur Psychiatr Rev. 2010, 3 (1): 21-25.
26.
Olivares JM, Peuskens J, Pecenak J, Resseler S, Jacobs A, Akhras KS, on behalf of the e-STAR study group: Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin. 2009, 25: 2197-2206. 10.1185/03007990903149306.CrossRefPubMed
27.
Mehnert A, Diels J: Impact of administration interval on treatment retention with long-acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry -Mental Health Policy and Economics. 2011, Venice, Italy
28.
Ascher-Svanum H, Faries D, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67: 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed
29.
Olivares JM, Rodrigues-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A: Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009, 24: 287-296. 10.1016/j.eurpsy.2008.12.002.CrossRefPubMed
30.
Kane J, Detke H, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D: Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010, 167: 181-189. 10.1176/appi.ajp.2009.07081221.CrossRefPubMed
31.
Morken G, Widen J, Gråwe R: Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008, 8: 32-10.1186/1471-244X-8-32.PubMedCentralCrossRefPubMed
32.
Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, Llorca PM: Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol. 2005, 19: 15-21. 10.1177/0269881105056514.CrossRefPubMed
33.
Lee M, Ko Y, Lee S, Lee M-S, Ko Y-H, Lee S-H, Seo Y-J, Kim S-H, Joe S-H, Han C-S, Jung-Ho Lee J-H, Jung I-K: Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol. 2006, 21: 399-407. 10.1002/hup.782.CrossRefPubMed
34.
Lindenmayer J-P, Khan A, Eerdekens M, Van Hove I, Kushner S: Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2007, 17: 138-144. 10.1016/j.euroneuro.2006.08.004.CrossRefPubMed
35.
Gopal S, Hough D, Xu H, Lulla JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW: Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose–response study. Int Clin Psychopharmacol. 2010, 25: 247-256. 10.1097/YIC.0b013e32833948fa.CrossRefPubMed
36.
Pandina GJ, Lane R, Gopal S, Gassm ann-Mayer C, Hough D, Remmerie B, Simpson G: A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011, 35: 218-226. 10.1016/j.pnpbp.2010.11.008.CrossRefPubMed
37.
Nasrallah H, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D: A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010, 35: 2072-2082. 10.1038/npp.2010.79.PubMedCentralCrossRefPubMed
38.
Pandina GJ, Lindenmayer J-P, Lull JM, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J: A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010, 30: 235-244. 10.1097/JCP.0b013e3181dd3103.CrossRefPubMed
39.
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS: Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005, 15: 111-117. 10.1016/j.euroneuro.2004.07.003.CrossRefPubMed
40.
Eerdekens M, Van Hove I, Remmerie B, Mannaert E: Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004, 70: 91-100. 10.1016/j.schres.2003.11.001.CrossRefPubMed
41.
42.
Urdahl H, Knapp M, Edgell ET, Ghandi G, Haro JM, on behalf of the SOHO Study Group: Unit costs in international economic evaluations: resource costing of the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand. 2003, 107 (Suppl. 416): 41-47.CrossRef
43.
Syriopoulou V, Kafetzis D, Theodoridou M, Syrogiannopoulos GA, Mantagos S, Trimis G, Mavrikou M, Konstantopoulos A: Evaluation of potential medical and economic benefits of universal rotavirus vaccination in Greece. Acta Pædiatr. 2011, 100: 732-739.CrossRefPubMed
44.
45.
Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes. 2008, 6: 105-10.1186/1477-7525-6-105.PubMedCentralCrossRefPubMed
46.
Cummins C, Stevens A, Kisely S: The use of olanzapine as a first and second choice treatment in schizophrenia. 1998, Department of Public Health & Epidemiology, Birmigham, UK, University of Birmingham. A West Midlands Development and Evaluation Committee Report
47.
Lenert L, Sturley A, Rapaport M, Chaveza S, Mohre PE, Rupnow M: Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res. 2004, 71: 155-165. 10.1016/j.schres.2003.10.010.CrossRef
48.
Oh P, Lanctôt K, Mittmann N, Iskedjian M, Einarson TR: Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001, 4: 137-156. 10.3111/200104137156.CrossRef
49.
Revicki D, Shakespeare A, Kind P: Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol. 1996, 11: 101-108.PubMed
50.
Peng X, Ascher-Svanum H, Faries D, Conley RR: Decline in the rate and cost of psychiatric hospitalization following initiation of depot antipsychotics in the treatment of schizophrenia. Value Health. 2010, 13 (3): A112-CrossRef
51.
Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G: Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health. 2004, 7: 569-584. 10.1111/j.1524-4733.2004.75008.x.CrossRefPubMed
Metadata
Title
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
Authors
Thomas R Einarson
Maria Geitona
Alexandros Chaidemenos
Vasiliki Karpouza
Theodoros Mougiakos
Periklis Paterakis
Dimitrios Ploumpidis
Dionyssios Potamitis-Komis
Roman Zilbershtein
Colin Vicente
Charles Piwko
Panagiotis Kakkavas
Konstantina Paparouni
Rasmus C D Jensen
Michiel E H Hemels
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Annals of General Psychiatry / Issue 1/2012
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/1744-859X-11-18

Other articles of this Issue 1/2012

Annals of General Psychiatry 1/2012 Go to the issue

Primary research

Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model

Primary research

Poor performance on the Iowa gambling task in children with obsessive-compulsive disorder

Primary research

Number of prior episodes and the presence of depressive symptoms are associated with longer length of stay for patients with acute manic episodes

Primary research

Reliability and validity of the KIDSCREEN-52 health-related quality of life questionnaire in a Greek adolescent population

Primary research

Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study

Review

Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges